Sample Collection From Healthy Volunteers for Assay Optimization
NCT03538600 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2026-04-24
Summary
Background:
The Laboratory of Immune System Biology (LISB) works with other labs at the National Institutes of Health. They study how parts of living things come together to make a whole. LISB designs and improves research tests on human samples like blood and cells. In order to do its work, LISB needs to have a lot of these samples available.
Objective:
To collect biological specimens to use for designing and improving research tests. Specimens include blood, stool, saliva, and skin/mucosal swabs.
Eligibility:
Healthy people ages 3-80
Design:
Participants will be screened with an interview about their general health and their medical history. They will have a physical exam and blood tests.
If the results of the screening are normal, participants will be asked to give one or more of these samples:
Blood will be drawn from an arm vein with a needle and syringe.
Mucus and skin will be collected by rubbing the area with a cotton swab. The areas may include the top of the tongue, inside the cheek, nostrils, behind the ear, elbow pit, or vagina.
Participants will spit into a tube to collect saliva.
Participants will pass stool into a plastic container that fits in the toilet under the seat. They will get sampling kits and instructions.
Over the next 5 years, if more samples are needed, participants will be contacted to set up another visit to the NIH. These visits will each take about 1 hour.
About every 2 years, when participants come to NIH for a visit, extra blood will be collected. It will be tested for HIV and hepatitis B and C.
Conditions
- Healthy Volunteers
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Kalpana Manthiram, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 3 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-06-28
- Primary Completion
- 2043-06-30
- Completion
- 2043-06-30
Countries
- United States
Study Locations
More Related Trials
-
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
NCT04852276 ·Status: COMPLETED
-
A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
NCT06523153 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Challenge Infection of Healthy Adult Volunteers With RSV A2
NCT03388645 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of a Human Metapneumovirus Challenge Virus in Healthy Adults
NCT01109329 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
NCT05367908 ·Status: COMPLETED
-
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
NCT05997290 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
NCT04412538 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
NCT05144139 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)
NCT05085639 ·Status: UNKNOWN ·Phase: PHASE1
-
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
NCT06199934 ·Status: COMPLETED
-
Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People
NCT05352867 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine
NCT05313035 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
NCT05439824 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
NCT04368728 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immune Response to Varicella-Zoster Vaccination and Infection
NCT00921999 ·Status: COMPLETED
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
NCT06585241 ·Status: RECRUITING ·Phase: PHASE4
-
This Trial is a Clinical Performance Validation Study That Will Evaluate the Clinical Agreement of the Sky Medical™ Rapid Antigen Test Comparing the Antigen Rapid Test to RT-PCR
NCT05491993 ·Status: UNKNOWN ·Phase: NA
-
Clinical Performance Evaluation of the Bio-Self™ COVID-19 Antigen Home Test
NCT05334758 ·Status: COMPLETED ·Phase: NA
-
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
NCT05258669 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
RSV Challenge in Healthy Adults
NCT00100373 ·Status: COMPLETED ·Phase: NA
-
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
NCT05354089 ·Status: UNKNOWN ·Phase: PHASE1
-
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
NCT05289037 ·Status: COMPLETED ·Phase: PHASE2
-
A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses
NCT03362593 ·Status: TERMINATED ·Phase: PHASE1
-
Collection of Convalescent SARS Plasma by Apheresis
NCT00342524 ·Status: COMPLETED
-
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
NCT05148962 ·Status: COMPLETED ·Phase: PHASE1